olivLaw · US equity research
TOMI Environmental Solutions, Inc. TOMZ
Industrial Organic Chemicals · SIC 2860 · Vertical: Industrial Organic Chemicals (SIC 2860)
TOMI Environmental Solutions develops disinfection and decontamination systems based on ionized hydrogen peroxide (iHP), sold as equipment and recurring consumables to pharma, hospitals, food safety and commercial customers. The company reported strong revenue growth in the second quarter of 2026, but it still has a history of losses, funding uncertainty and a proposed merger. Annual revenue fell 27%, to 5.6 million USD, in 2025.
At the close of 04 Nov 2026, TOMI Environmental Solutions, Inc. (TOMZ) stock was 2.23 USD (−0.45% on the day), with market capitalisation 18.2 m USD, beta 0.41, 52-week range 1.27–3.24 USD. Latest reported quarter (Q2 2026): revenue of 2.2 m USD (+117.9% YoY), net income of -382.3 k USD, diluted EPS -0.05 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 76.5
- overbought (≥ 70)
- Bollinger (20, 2)
- 1.11 – 2.18
- above the upper band · %B 1.05 · band width 65.0%
- SMA 50 / 200
- 1.59 / 1.97
- mixed trend
- MACD (12, 26, 9)
- 0.15 / 0.05
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +41.1% | −1.1% | +42.2 pp | — |
| 3 months | +16.8% | −0.5% | +17.2 pp | — |
| 6 months | +12.6% | +4.4% | +8.2 pp | — |
| Year to date | −4.7% | +12.3% | −17.0 pp | — |
| 1 year | −19.2% | +13.5% | −32.7 pp | −1.7% |
| 3 years | −23.4% | +76.4% | −99.8 pp | −33.8% |
| 5 years | −44.5% | +63.7% | −108.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.5 m | 1.1 m | 1.6 m | 1.0 m | 2.0 m | 1.0 m | 1.7 m | 2.2 m |
| Cost of revenue | 981.1 k | 1.6 m | 624.8 k | 354.0 k | 779.6 k | 800.5 k | 822.5 k | 861.6 k |
| Gross profit | 1.6 m | -529.2 k | 951.7 k | 677.1 k | 1.2 m | 216.2 k | 831.8 k | 1.4 m |
| Research & development | 56.3 k | 104.8 k | 44.6 k | 84.1 k | 10.7 k | 150.5 k | 56.8 k | 38.1 k |
| Operating income | 149.1 k | -3.1 m | -754.5 k | -1.1 m | -321.4 k | -1.6 m | -626.3 k | -244.1 k |
| Depreciation & amortisation | 69.9 k | 72.2 k | 68.5 k | 69.2 k | 68.6 k | 65.0 k | 52.9 k | 50.1 k |
| Interest expense | 93.6 k | 31.3 k | 118.9 k | 106.2 k | 130.3 k | 1.2 k | 94.1 k | 94.1 k |
| Pre-tax income | 59.0 k | -3.3 m | -255.6 k | -1.2 m | -450.3 k | -1.8 m | -810.6 k | -382.3 k |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 59.0 k | -3.3 m | -255.6 k | -1.2 m | -450.3 k | -1.8 m | -810.6 k | -382.3 k |
| Diluted EPS | 0.00 | -0.16 ≈ | -0.01 | -0.19 | -0.02 | -0.09 ≈ | -0.04 | -0.05 |
| Operating cash flow | 105.3 k ≈ | 12.7 k | -275.7 k | -187.6 k ≈ | -113.5 k ≈ | -619.9 k | 295.6 k | -1.6 m ≈ |
| Capex | 5.4 k ≈ | 3.2 k | 0 | 2.7 k ≈ | 0 ≈ | 2.5 k | 5.3 k | -1 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.6 m | 6.3 m | 25.0 m | 7.8 m | 8.3 m | 7.4 m | 7.7 m | 5.6 m |
| Revenue YoY | +11.8% | +13.7% | +294.3% | −69.0% | +7.5% | −11.8% | +5.2% | −27.2% |
| Net income | -3.2 m | -2.3 m | 4.4 m | -4.4 m | -2.9 m | -3.4 m | -4.5 m | -3.7 m |
| Net income YoY | unavailable | unavailable | unavailable | −201.0% | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -0.15 | 0.23 | -0.25 | -0.15 | -0.17 | -0.22 | -0.19 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | −208.7% | unavailable | unavailable | unavailable | unavailable |
| net % | -57.8% | -36.2% | 17.5% | -57.2% | -34.5% | -46.3% | -57.8% | -66.5% |
| Free cash flow | -2.4 m | -960.0 k | 4.3 m | unavailable | -1.4 m | -3.7 m | -1.5 m | -1.2 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 87.8 k USD
- Financial debt
- 3.3 m USD
- Net debt
- 3.2 m USD
- Equity
- 588.5 k USD
- Total assets
- 7.0 m USD
- Debt / equity
- 5.57x
- Current ratio
- 1.32x
- ROE
- -160.0%
- ROA
- -44.8%
- FCF margin
- -21.3%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 25.0 m | 7.8 m | 8.3 m | 7.4 m | 7.7 m | 5.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Cost of revenue | 10.0 m | 3.2 m | 3.3 m | 3.1 m | 4.2 m | 2.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Gross profit | 15.0 m | 4.6 m | 5.1 m | 4.3 m | 3.6 m | 3.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Research & development | 455.0 k | 572.7 k | 352.2 k | 491.8 k | 290.7 k | 289.9 k | SEC (XBRL)· 31 Mar 2026verified |
| Operating income | 4.5 m | -4.9 m | -2.9 m | -3.3 m | -4.1 m | -3.9 m | SEC (XBRL)· 31 Mar 2026verified |
| Depreciation & amortisation | 719.8 k | 294.7 k | 329.2 k | 366.7 k | 296.5 k | 271.3 k | SEC (XBRL)· 31 Mar 2026verified |
| EBITDA | 5.2 m ≈ | -4.6 m ≈ | -2.6 m ≈ | -3.0 m ≈ | -3.8 m ≈ | -3.6 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Interest expense | 43.5 k | 1.0 k | 0 | 63.3 k | 312.0 k | 356.7 k | SEC (XBRL)· 31 Mar 2026verified |
| Pre-tax income | 4.5 m | -4.5 m | -2.9 m | -3.4 m | -4.5 m | -3.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Income tax | 77.0 k | -74.1 k | 0 | 0 | 0 | 0 | SEC (XBRL)· 31 Mar 2026verified |
| Net income | 4.4 m | -4.4 m | -2.9 m | -3.4 m | -4.5 m | -3.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Diluted EPS | 0.23 | -0.25 | -0.15 | -0.17 | -0.22 | -0.19 | SEC (XBRL)· 31 Mar 2026verified |
| Weighted average diluted shares | 18.8 m | 17.5 m | 19.7 m | 19.8 m | 20.0 m | 20.1 m | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 5.2 m | 5.3 m | 3.9 m | 2.3 m | 88.0 k | 87.8 k | SEC (XBRL)· 31 Mar 2026verified |
| Receivables | 3.7 m | 2.0 m | 2.8 m | 2.4 m | 1.9 m | 689.2 k | SEC (XBRL)· 31 Mar 2026verified |
| Inventories | 3.8 m | 4.7 m | 4.5 m | 4.6 m | 3.6 m | 2.9 m | SEC (XBRL)· 31 Mar 2026verified |
| Current assets | 13.7 m | 12.9 m | 12.1 m | 10.0 m | 6.5 m | 4.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Property, plant & equipment, net | 1.3 m | 1.5 m | 1.3 m | 1.0 m | 875.4 k | 614.3 k | SEC (XBRL)· 31 Mar 2026verified |
| Intangibles (excl. goodwill) | 722.9 k | 956.3 k | 1.0 m | 1.1 m | 1.3 m | 1.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Total assets | 16.8 m | 16.3 m | 15.5 m | 13.4 m | 9.7 m | 7.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Accounts payable | 1.5 m | 1.1 m | 1.8 m | 1.3 m | 1.9 m | 1.5 m | SEC (XBRL)· 31 Mar 2026verified |
| Short-term debt | — | — | — | — | 129.1 k | 143.7 k | SEC (XBRL)· 31 Mar 2026verified |
| Long-term debt | — | — | — | — | — | 3.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Current liabilities | 2.2 m | 1.8 m | 3.3 m | 2.1 m | 2.7 m | 3.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Total liabilities | 3.6 m | 2.7 m | 4.1 m | 5.0 m | 5.6 m | 6.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Equity | 13.2 m † | 13.6 m † | 11.4 m † | 8.4 m † | 4.1 m † | 588.5 k † | SEC (XBRL)· 31 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.6 m | -3.8 m | -1.2 m | -3.6 m | -1.4 m | -1.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Capex | 289.3 k | — | 200.9 k | 98.1 k | 107.9 k | 5.2 k | SEC (XBRL)· 31 Mar 2026verified |
| Free cash flow | 4.3 m ≈ | — | -1.4 m ≈ | -3.7 m ≈ | -1.5 m ≈ | -1.2 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Investing cash flow | -400.7 k | -639.4 k | -241.4 k | -216.7 k | -261.5 k | -135.6 k | SEC (XBRL)· 31 Mar 2026verified |
| Financing cash flow | 124.2 k | 4.6 m | 25.0 k | 2.3 m | 27.5 k | 755.1 k | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 18.2 m USD
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -56.2% | 0 (vs peers) | 24% |
| Net margin · Quality | -49.8% | 16 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -12.2% | 0 (on a fixed band) | 19% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -8.9x | 0 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 1.5x | 57 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -11.2% | 0 (on a fixed band) | 19% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet23/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality6/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
TOMI ENVIRONMENTAL SOLUTIONS, INC. (TOMZ). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 5.6 m USD in 2025; YoY growth -27.2%; net margin -49.8%; ROE -168.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- ROIC: -56.2%
- Net margin: -49.8%
- Revenue CAGR 3Y: -12.2%
- Interest coverage: -8.9x
- FCF yield: -11.2%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Industrial Organic Chemicals (SIC 2860) · same industry (4-digit SIC) · compared with 20 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IFFInternational Flavors & Fragrances Inc | 22.0 bn | 122.1 | 1.3% | 1.6% | −5.2% | +26% / +16% |
| LYBLyondellbasell Industries N.V. | 20.4 bn | 15.6 | 11.9% | 4.1% | −9.7% | +29% / −34% |
| WLKWestlake Corporation | 8.7 bn | — | -4.9% | -3.9% | −8.0% | +2% / −47% |
| NEUNewmarket Corporation | 6.7 bn | 14.7 | 25.3% | 16.5% | −2.2% | −5% / +37% |
| SXTSensient Technologies Corp | 5.4 bn | 31.7 | 13.7% | 9.7% | +3.5% | +29% / +117% |
| MEOHMethanex Corporation | 5.0 bn | 70.1 | 6.4% | 4.0% | −3.5% | +83% / +53% |
| REXRex American Resources Corporation | 1.3 bn | 10.5 | 22.5% | 20.9% | +1.2% | +20% / +62% |
| GPREGreen Plains Inc. | 957.5 m | 8.6 | 15.4% | 6.8% | −14.9% | +32% / −45% |
| WLKPWestlake Chemical Partners LP | 761.8 m | 12.9 | — | 4.8% | +2.7% | +14% / −5% |
| GEVOGevo, Inc. | 316.5 m | — | -57.0% | -119.9% | +849.3% | −40% / +13% |
| ALTOAlto Ingredients, Inc. | 271.5 m | 5.3 | 22.2% | 5.5% | −4.9% | +37% / +43% |
| FFFuturefuel Corp. | 246.5 m | — | -18.3% | -19.9% | −60.7% | +70% / −5% |
| CDXSCodexis, Inc. | 118.3 m | — | -69.4% | -39.6% | +18.6% | −38% / −54% |
| LODEComstock Inc. | 113.3 m | — | -38.2% | -3,680.5% | −48.5% | −58% / −68% |
| AMTXAemetis, Inc | 90.2 m | — | — | -27.4% | −26.2% | −28% / −72% |
| TANHTantech Holdings Ltd | 90.1 m | — | -25.7% | -80.9% | −10.7% | −76% / −100% |
| LNZALanzaTech Global, Inc. | 69.2 m | 0.4 | 146.4% | 295.7% | +12.6% | −63% / −99% |
| SAFXXcf Global, Inc. | 41.0 m | — | -246.1% | — | unavailable | −87% / unavailable |
| TOMZTomi Environmental Solutions, Inc. | 18.2 m | — | -168.8% | -49.8% | −27.2% | −19% / −23% |
| CNEYCn Energy Group. Inc. | 2.5 m | — | -11.2% | -31.3% | −30.2% | −65% / −99% |
| BAKBraskem SA | — | — | — | -14.6% | +9.7% | −61% / −86% |
1- and 3-year price returns: for TOMZ from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
TOMI Environmental Solutions develops disinfection and decontamination systems based on ionized hydrogen peroxide (iHP), sold as equipment and recurring consumables to pharma, hospitals, food safety and commercial customers. The company reported strong revenue growth in the second quarter of 2026, but it still has a history of losses, funding uncertainty and a proposed merger 123. Annual revenue fell 27%, to 5.6 million USD, in 2025 1.
SWOT
Strengths
- The BIT technology is protected by patents and has EPA registration, and the company holds approvals in numerous countries 1. The recurring consumable model provides a fairly predictable revenue stream 12.
- The customer base includes leading pharmaceutical companies and institutions, which validates the technology in regulated environments 1.
- The gross margin increase in the second quarter of 2026 shows that high-margin products have become an important component 23.
Weaknesses
- The company has a history of net losses and a significant accumulated deficit, and cash was very low at the end of 2025 1.
- The company has no long-term customer contracts, and orders can be cancelled 1.
- Near-total dependence on the SteraMist brand makes the company vulnerable to market changes for that product 1.
Opportunities
- Expansion into the medical sector through an FDA 510(k) submission for a medical device could open a new market 12.
- OEM partnerships with cleanroom manufacturers could extend distribution without proportionally higher direct sales costs 1.
- New EPA registrations and EU and UK approvals could open markets in agriculture and food safety 23.
Risks
- Going concernhigh
The auditor has expressed substantial doubt about the company's ability to continue as a going concern over the next year, and management's plan depends on executing its financing 1. If financing does not materialise, operations could be seriously affected.
- Proposed merger with Carbonium Corehigh
The transaction depends on shareholder and regulatory approvals and on a required concurrent financing 23. If the transaction fails, the company's plans could change.
- Single-product dependencemedium
The company's success depends almost entirely on the SteraMist family, so market or regulatory problems for this product would have a major impact 1.
- No long-term customer contractsmedium
Orders can be cancelled, and sales history is not a reliable indicator of future revenue 1.
- International and export riskslow
International sales are exposed to trade regulations, tariffs and export control requirements, with potentially serious penalties 1.
Investment thesis
What would need to be true (bull case)
- If revenue growth from the second quarter of 2026 is sustained and the backlog converts, the company could show that its recurring consumable model is working 23.
- Expansion into defense, pharmaceutical and food sectors could diversify revenue sources 12.
- Improvement in gross margin and operating loss suggests a path toward operational breakeven 23.
What would break the thesis
- The history of losses, lack of cash and doubts about going concern could limit the company's ability to fund growth 1.
- Shareholder dilution through the equity line and convertible instruments could become significant if financing comes from no other source 1.
- The revenue growth in the second quarter of 2026 could reflect one-off equipment sales rather than a durable trend 2.
What to watch
- Decizia FDA privind cererea 510(k) pentru dispozitivul medical2027
- Completion of the Carbonium Core merger and the concurrent financing2026
- Delivery against the 2026 full-year revenue guidancenext 10-K
- Conversion of the backlog and commercial pipeline into revenueQ3 2026
- FDA decision on the 510(k) submission for the medical device2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
TOMI Environmental Solutions, Inc. is a global provider of disinfection and decontamination solutions built on its patented Binary Ionization Technology (BIT), whose flagship product is SteraMist. The technology converts a 7.8% hydrogen peroxide solution into submicron hydroxyl radical particles that the company says achieve a 6-log or greater kill rate 1. It operates through four divisions: Life Sciences, Hospital-Healthcare, Food Safety and Commercial 1. Revenue comes from equipment sales, BIT Solution consumables, decontamination services and IQ/OQ/PQ qualification services 1. The razor-blade model, in which consumables generate recurring revenue, is central to the strategy 12. The sources also show near-total dependence on the SteraMist brand 1.
Segments
Life Sciences
This is the largest area of pharmaceutical and CDMO customers, for which the company developed the CES, Hybrid and SIS lines, with full IQ/OQ/PQ validation 1. Source 1 notes that the onshoring of pharmaceutical manufacturing to the US provides a supportive backdrop for near-term adoption 1.
Market context
The company is active in decontamination markets across pharma, hospitals, food and commercial, where it competes with traditional manual cleaning methods and other technologies 1. According to source 1, healthcare-associated infections affect 7-10% of hospitalized patients globally each year, creating demand for advanced disinfection 1. Source 2 reports that revenue in the second quarter of 2026 grew 118% year over year, supported by equipment and CES systems 2.
Trends
- Pharmaceutical manufacturing onshoringtailwind
Announced US pharmaceutical manufacturing investments exceeding 370 billion USD could generate demand for decontamination systems integrated into new facilities 1. The timing, however, depends on construction decisions affected by tariff uncertainty 1.
- Hydrogen peroxide food regulationtailwind
The broader permitted use of hydrogen peroxide in food could widen iHP applications on surfaces and food products, particularly in the ready-to-eat segment 1.
- Tariffs and macro uncertaintyheadwind
Uncertainty over tariff policy delayed the conversion of some CES projects into revenue, and geopolitical tensions could raise energy costs and disrupt supply chains 1.
- Funding dependencemixed
The lack of cash reserves raises questions about funding, and the equity line depends on the share price and trading volume 1. If the proposed merger with Carbonium Core is completed, the financial structure could change substantially 23.
Competitive position
The sources do not name competitors explicitly. The company does, however, point to competition from alternative technologies and existing disinfection products, as well as from providers offering similar services through franchise networks 1. Non-exclusive agreements with restoration specialists allow competitors to sell to the same customers 1.
- Alternative disinfection product providers
Source 1 indicates that alternative products and competing technologies could reduce demand for SteraMist 1.
- Decontamination franchise networks
Source 1 mentions networks such as DKI, First Onsite and Steri-Clean, which may work with competing products 1.
- Traditional sterilization technologies
Source 1 indicates that vapor-based peroxide methods and gaseous chemical agents are alternatives customers weigh 1.
- Manual cleaning with conventional chemicals
Source 1 shows that conventional disinfectants, such as quaternary compounds and bleach, are gradually being replaced by the company's mechanical systems 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- ‘Attacked behind the scenes’: Children of Blood & Bone author Tomi Adeyemi distances herself from film adaptationThe Guardian World · 06 Jul 2026 · RO
The latest news item in our archive is from 06 Jul 2026; the newest SEC filing is from 16 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report16 Oct 2026Departure or appointment of officers
- Current report21 Sept 2026Termination of a material agreement · Regulation FD disclosure · Financial statements and exhibits
- Current report02 Sept 2026Other events
- Current report14 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Current report29 Jul 2026Results of operations · Financial statements and exhibits
- Current report20 Jul 2026Amendments to articles or bylaws · Financial statements and exhibits
- Current report16 Jul 2026Other events
- Current report29 Jun 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Current report10 Jun 2026Shareholder vote
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / TOMI Environmental Solutions, Inc. · 31 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / TOMI Environmental Solutions, Inc. · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / TOMI Environmental Solutions, Inc. · 14 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.